CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Apolipoprotein A5 (apoA5), besides accelerating plasma triglyceride hydrolysis, mediates triglyceride reduction via an LDL receptor related protein 1 (LRP1) dependent pathway
DOI 10.1055/s-0031-1277377
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Merkel, K Brügelmann, J Heeren
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Apolipoprotein A5 (apoA5) is regulates plasma triglyceride (TG) levels. Genetic aberrations (SNP's) in its gene lead to increased plasma TG in humans; apoA5 deficiency by structural mutations yields into severe hypertriglyceridemia type I or V. ApoA5 reduces plasma TG levels by activating or stabilizing endothelial lipoprotein lipase (LPL). However, due to its binding properties and its high intra-hepatocellul…
Zitieren
Zitierempfehlung
M Merkel, K Brügelmann, J Heeren (2011) Apolipoprotein A5 (apoA5), besides accelerating plasma triglyceride hydrolysis, mediates triglyceride reduction via an LDL receptor related protein 1 (LRP1) dependent pathway. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0031-1277377
Mit CareLit weiterarbeiten